-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
WuXi Biologics, the world's leading open biopharmaceutical technology platform company, and OncoC4, a clinical-stage biopharmaceutical company, announced today that the two parties have established an exclusive CDMO partnership for the entire R&D pipeline of OncoC4
.
OncoC4's research and development pipeline includes a new generation of CTLA-4 antibody ONC-392, which is currently undergoing phase I clinical trials in the United States and China
According to the agreement, WuXi Biologics will provide integrated R&D and production services as an exclusive CDMO partner to meet the needs of OncoC4's biological drugs from early research, preclinical to commercialization
.
OncoC4 will make full use of WuXi Biologics' technological capabilities and experience in the development of cell lines and preparations, as well as the production of biological drug stock solutions and preparations, to accelerate the product development process
In addition, OncoC4 has further expanded its cooperation with WuXi Biologics into the field of bispecific antibodies
.
According to the agreement, OncoC4 is authorized to use the WuXiBody® technology platform to discover and develop dual-antibody drugs; in addition to the down payment, WuXi Biologics will also receive milestone payments for the development and commercialization of dual-antibody drugs on the WuXiBody® platform, as well as net sales after the product is launched.
As early as 2017, WuXi Biologics provided OncoC4 (formerly OncoImmune) ONC-392 with integrated CMC services, and the two parties have established a close and stable cooperative relationship
.
The new agreement reached this time also marks that the partnership between WuXi Biologics and OncoC4 has reached a new level
Dr.
Yang Liu, Founder, Chairman and CEO of OncoC4, said: “We are very pleased to sign a long-term cooperation agreement with
WuXi Biologics to deepen the strategic partnership between the two parties.
OncoC4’s R&D pipeline includes targeted innate and adaptive immune checkpoints.
Dr.
Zhisheng Chen, CEO of WuXi Biologics, said: "We are very honored to be the exclusive CDMO partner of OncoC4 to provide services for all of its R&D pipelines.
This is another proof of the success of our two-round strategy of'follow the molecule' and'win the molecule'.
This deepening of cooperation also proves that
WuXi Biologics' excellent quality system and excellent execution ability have been highly recognized by partners .
We look forward to continuing to empower OncoC4, speeding up its product launch process, and improving the availability of innovative biopharmaceuticals at an early date.
Benefit more patients worldwide
